Immunis
Immunis is a clinical-stage biotechnology company developing multi-active stem cell-derived secretome biologics targeting age-related immune decline, with lead candidate IMM01-STEM in trials for muscle atrophy and sarcopenic obesity.
- Company typePrivate
- Founded2018
- HeadquartersIrvine, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Immunis does
Immunis is a clinical-stage biotechnology company headquartered in Irvine, California, developing multi-active stem cell-derived secretome biologics that target age- and disease-related immune decline. Its core platform produces biologics derived from the secretome of partially differentiated human pluripotent stem cells, delivering a naturally balanced combination of regenerative and immunomodulatory molecules in physiological concentrations. The company's lead investigational product, IMM01-STEM, is a cell-free multi-active biologic designed to influence multiple cell-signaling pathways simultaneously — addressing muscle loss, muscle regeneration, and metabolic dysfunction without the risks associated with administering live stem cells.
The company is advancing a portfolio of clinical programs built on its secretome platform. STEM-MYO, a Phase 1/2a trial for muscle atrophy associated with knee osteoarthritis, completed in late 2024. STEM-META, a Phase 2 placebo-controlled study in seniors with sarcopenic obesity, reported a 26% improvement in gait speed versus placebo in topline interim results announced in January 2026, with absolute improvement exceeding the clinically meaningful 0.1 m/s threshold. The company is also developing STEM-K9 for canine muscle atrophy in partnership with VetBio Partners, and in March 2026 expanded into central nervous system indications through an exclusive licensing agreement with Toray Industries for IMM02-KORA, a selective opioid kappa receptor agonist targeting L-DOPA-induced dyskinesia in Parkinson's disease.
Immunis operates a pre-revenue, capital-intensive business model typical of clinical-stage biotech, with future revenue expected from therapeutic product commercialization and licensing of pipeline assets. The company has raised approximately $35 million across a $10M Series A (August 2022) and $25M Series A-1 (January 2025), with disclosed participation from Remiges Ventures, Continuum Health Ventures, BOLD Capital Partners, LifeSpan Vision Ventures, JLS Fund, and a leading global insurance company. Its go-to-market motion is enterprise-focused, relying on institutional clinical partnerships (CIRM Alpha Stem Cell Clinics Network, UC Irvine Medical Center), scientific advisory engagement (including XPRIZE founder Dr. Peter Diamandis), and industry-conference visibility, with future commercial distribution anticipated to follow traditional pharmaceutical channels or licensing structures upon FDA approval.
Immunis firmographics
Firmographics- Name
- Immunis
- Legal name
- Immunis, Inc.
- Website
- https://immunisbiomedical.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Immunis is a clinical-stage biotechnology company developing multi-active stem cell-derived secretome biologics targeting age-related immune decline, with lead candidate IMM01-STEM in trials for muscle atrophy and sarcopenic obesity.
- Ownership category
- akta.pro rank
Immunis industry classification
Industry- Product category
- Regenerative Medicine Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)
- akta.pro secondary industries
- Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Immunis is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Immunis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Therapeutic Product Development: Pre-revenue clinical-stage biotech developing novel biologics for age-related diseases. Revenue potential from FDA-approved therapeutic products for muscle atrophy, sarcopenia, metabolic conditions, and Parkinson's disease dyskinesia. Business model centers on bringing secretome-based therapies through clinical development to market approval and commercialization.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels5 records
Immunis product offering
Product offeringCore offering
Immunis is a clinical-stage biotechnology company that develops and advances multi-active, stem cell-derived secretome biologics through FDA-regulated clinical trials. Its lead investigational product, IMM01-STEM, delivers naturally balanced regenerative and immunomodulatory factors to treat age- and disease-related muscle atrophy, sarcopenic obesity, and metabolic dysfunction. The company also in-licensed and is developing IMM02-KORA, a selective opioid kappa receptor agonist, for dyskinesia associated with Parkinson's disease, with commercialization intended through exclusive licensing partnerships.
Product overview
Immunis is a clinical-stage biotechnology company developing a portfolio of multi-active stem cell-derived secretome biologics. The primary investigational product is IMM01-STEM, a complex biologic comprised of regenerative factors that impact multiple signaling pathways, currently being evaluated across multiple clinical programs: STEM-MYO (Phase 1/2a for muscle atrophy associated with knee osteoarthritis) and STEM-META (Phase 2 for sarcopenic obesity). The company has also expanded its pipeline through an exclusive licensing agreement with Toray to develop IMM02-KORA for Parkinson's disease dyskinesia. All products leverage the company's secretome technology platform to deliver all-natural, all-human immune modulators in their natural physiological concentrations.
Differentiator
Problem solved
Functional benefit
Brands
- IMM01-STEM: Investigational immunomodulatory secretome product derived from partially differentiated stem cells, targeting muscle atrophy and metabolic dysfunction
- IMM02-KORA (KORA)
- STEM-MYO Program
- STEM-META Program
- STEM-K9 Program
Products and services
- IMM01-STEM A novel, multi-active, cell-free biologic derived from the secretome of partially differentiated stem cells, delivering naturally balanced regenerative and immunomodulatory molecules in physiological concentrations to treat age- and disease-related muscle atrophy, muscle regeneration impairment, and metabolic dysfunction in patients.
- IMM02-KORA (KORA) Selective opioid kappa receptor agonist drug candidate for the treatment of dyskinesia associated with Parkinson's disease, licensed exclusively from Toray Industries for development and commercialization in the United States, Canada, the European Union, and EFTA.
- STEM-MYO Program Phase 1/2a clinical trial program evaluating IMM01-STEM safety and tolerability in elderly participants with muscle atrophy associated with knee osteoarthritis, conducted at UCI Health CIRM Alpha Stem Cell Clinics.
- STEM-META Program Phase 2 placebo-controlled dose expansion study of IMM01-STEM evaluating safety and efficacy on muscle strength and physical function in seniors with obesity and muscle weakness (sarcopenic obesity).
- STEM-K9 Program Preclinical program evaluating IMM01-STEM for canine muscle atrophy in partnership with VetBio Partners, pursuing parallel development in companion animals.
Quantifiable outcome
- 26% improvement in gait speed compared to placebo controls
- +4 more outcomes
Companies that use Immunis
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles2 records
Immunis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature3 records
Immunis partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, supporting and strategic.
- Toray IndustriescoreExclusive licensing agreement with Japanese pharmaceutical company Toray Industries to develop and commercialize TRK-820 (renamed IMM02-KORA/KORA), a novel selective opioid kappa receptor agonist for treatment of dyskinesia associated with Parkinson's disease. Immunis obtained exclusive rights for US, Canada, EU, and EFTA. Toray receives upfront payment, development milestones, and sales royalties.
- VetBio Partners, LLCsupportingPartnership with VetBio Partners for non-terminal safety studies targeting canine muscle atrophy. Pursuing parallel STEM-K9 program in dogs following preclinical success in aged mouse models and advancing clinical testing.
- Professor Irina Conboy (UC Berkeley)supportingProfessor of Bioengineering at UC Berkeley and Editor in Chief of Rejuvenation Research joined Immunis Scientific Advisory Board. Her research on age-related and pathological changes in tissue maintenance and repair supports company's therapeutic development approach.
- FDAcoreFDA awarded Phase 1/2a clinical trial for IMM01-STEM in muscle atrophy; FDA granted clearance for Phase II sarcopenic obesity trial; IND submitted for IMM02-KORA Parkinson's dyskinesia candidate.
- Springbok AnalyticsstrategicPartnership with Springbok Analytics, a life sciences muscle analytics company using MRI-based AI muscle analysis technology. Immunis uses Springbok's technology to evaluate efficacy of IMMUNA secretome therapeutic in restoring muscle growth and function in sarcopenic Phase 1/2a clinical trial population.
- CIRM Alpha Stem Cell Clinics NetworkcoreClinical trial agreement with California Institute of Regenerative Medicine Alpha Stem Cell Clinics Network to initiate STEM-MYO Phase 1/2a clinical trials. Network provides infrastructure and expertise for accelerated delivery of stem cell-based treatments through partnerships between patients, medical providers, and clinical trial sponsors.
- University of Utah (Dr. Micah Drummond)strategicResearch collaboration with Professor Micah J. Drummond at University of Utah investigating efficacy of immunomodulatory secretome on aged skeletal muscle. Peer-reviewed research published in GeroScience demonstrating IMM01-STEM improved muscle mass and strength during disuse and recovery in aged mouse models.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Immunis competitors and assessment
Company assessmentDirect peers
- BioAge Labs: Clinical-stage aging biotech developing therapeutics for age-related diseases, including obesity and muscle-related indications. Direct competitor in the longevity biotech space pursuing multi-indication pipelines with similar funding profiles.
- Unity Biotechnology: Clinical-stage biotech developing therapeutics that target senescent cells to treat age-related diseases. Comparable in indication focus (sarcopenia, ophthalmology) and platform-based approach to age-related disease intervention.
- Aeovian Pharmaceuticals: Biotech developing selective mTORC1 inhibitors for age-related diseases including sarcopenia. Closely comparable indication focus and therapeutic approach to age-related muscle and metabolic decline.
- Stealth BioTherapeutics: Clinical-stage biotech developing mitochondrial-targeted therapeutics for age-related and rare diseases. Comparable in therapeutic class (novel biologics for aging indications) and clinical-stage development profile.
- Pluristem Therapeutics: Clinical-stage cell therapy company using placenta-derived cell products for inflammatory, muscle injury, and age-related indications. Closely comparable cell-based therapeutic approach targeting similar muscle and inflammatory disease indications.
Broad incumbents
- Mesoblast: Commercial-stage cell therapy company developing mesenchymal lineage cell therapies for inflammatory and age-related conditions including musculoskeletal disorders. Broader incumbent in the regenerative medicine space with overlapping muscle atrophy indications.
- Altos Labs: Well-capitalized biotech pursuing cellular rejuvenation programming to reverse disease, injury, and the disabilities that occur with age. Broad incumbent in aging biology research with significantly greater resources than Immunis.
- Calico Life Sciences: Alphabet-backed R&D company focused on understanding the biology of aging and developing interventions for age-related diseases. Established incumbent in aging therapeutics with massive capital base and similar indication focus.
- Celularity: Clinical-stage cell therapy company developing allogeneic cellular therapies derived from the postpartum placenta, including regenerative medicine products. Comparable cellular/regenerative biology approach with Dr. Diamandis as co-founder.
Emerging players
- Loyal for Dogs: Veterinary longevity therapeutics company developing drugs to extend dog healthspan. Emerging player in the canine muscle atrophy/anti-aging veterinary space, directly comparable to Immunis's STEM-K9 program.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Immunis social profiles
Digital presenceImmunis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immunis leadership team
Management profileNumber of profiles
Profiles8 records
Immunis funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immunis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immunis
What does Immunis do?
Immunis is a clinical-stage biotechnology company that develops and advances multi-active, stem cell-derived secretome biologics through FDA-regulated clinical trials. Its lead investigational product, IMM01-STEM, delivers naturally balanced regenerative and immunomodulatory factors to treat age- and disease-related muscle atrophy, sarcopenic obesity, and metabolic dysfunction. The company also in-licensed and is developing IMM02-KORA, a selective opioid kappa receptor agonist, for dyskinesia associated with Parkinson's disease, with commercialization intended through exclusive licensing partnerships.
Is Immunis a public or private company?
Immunis is a private company. It is classified as venture growth investor backed and is currently operating.
When was Immunis founded?
Immunis was founded in 2018. It employs 11 to 50 people.
Where is Immunis based?
Immunis is headquartered in Irvine, United States, in the North America region.
How does Immunis make money?
One revenue line is on record: therapeutic Product Development.
Who are Immunis's main competitors?
Direct peers on record are BioAge Labs, Unity Biotechnology, Aeovian Pharmaceuticals, Stealth BioTherapeutics and Pluristem Therapeutics. Broad incumbents are Mesoblast, Altos Labs, Calico Life Sciences and Celularity. Loyal for Dogs is listed as an emerging player.
Does Immunis have an API?
No public API is recorded for Immunis.
What industry is Immunis in?
Immunis's product category is Regenerative Medicine Biologics. Its primary akta.pro industry code is HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics), with a secondary code of HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins. Its NAICS code is 325414 and its SIC code is 2836.